Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
- Wednesday, February 16, 2022, 7:10
- Business
- Add a comment
NEW YORK, Feb. 16, 2022 /PRNewswire/ — Cambrian Biopharma, a multi-asset longevity biotech, today announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway. The…
About the Author
adminasapcorp has written 41828 stories on this site.